IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPolitics

Dyne and Sarepta Shares Fall After Novartis Trial Fails

Shares of Dyne Therapeutics and Sarepta tumbled after a Novartis muscle disease treatment failed in a late stage trial. The setback raised concerns among investors regarding similar rare disease therapies currently in development.

Xurve View
Insights:

Related News
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 , Cayman Islands

Copyright IUX24 Media LTD. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and intelligence platform. This site provides market news and analytical data only; it does not constitute investment advice, individual trading signals, or brokerage services. All information is for educational and informational purposes. Trading involves significant risk, and we recommend consulting with a qualified financial professional before making any investment decisions.